NCT01207453View on ClinicalTrials.gov

Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis

PHASE4CompletedINTERVENTIONAL

Enrollment

49

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

Arthritis, Rheumatoid

Interventions

DRUG

Milnacipran

Milnacipran comes in 50 mg tablets and is taken orally. Participants will gradually be increased to a target dose of 50 mg twice daily.

DRUG

Placebo

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

Forest Laboratories

All Listed Sponsors

collaborator

Forest Laboratories

INDUSTRY

collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

lead

Brigham and Women's Hospital

OTHER